Log In
Print
BCIQ
Print
Print this Print this
 

Dificid, Dificlir, fidaxomicin (OPT-80)

Also known as: formerly difimicin, PAR-101

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionMacrocyclic narrow-spectrum antibiotic
Molecular Target Not available
Mechanism of ActionPolymerase inhibitor
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentMarketed
Standard IndicationClostridium
Indication DetailsPrevent Clostridium difficile-associated diarrhea (CDAD); Treat Clostridium difficile infection (CDI); Treat Clostridium difficile-associated diarrhea (CDAD); Treat Clostridium difficile-associated diarrhea (CDAD) in patients with cancer; Treat clostridium difficile infection (CDI) in pediatric patients
Regulatory Designation U.S. - Priority Review (Treat Clostridium difficile-associated diarrhea (CDAD))
Partner Astellas Pharma Inc.; AstraZeneca plc; OBI Pharma Inc.; Specialised Therapeutics Australia Pty. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

6

$10,663.1M

$9,070.1M

$516.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today